Surgery
Advances with pharmacotherapy for peritoneal metastasis
Expert Opinion on Pharmacotherapy 2020 August 12 [Link] Yutaka Yonemura, Haruaki Iahibashi, Shouzou Sako, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Shunsuke Motoi, Yang Liu, Satoshi Wakama, Yasuyuki Kamada, Kazurou Nishihara Abstract Introduction: A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MoreProgress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma
Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…
Read MoreAddition of Radiotherapy to Surgery and Chemotherapy Improves Survival in Localized Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study
Lung Cancer 2020 May 30 [Link] Andrew B Thompson, Thomas J Quinn, Zaid A Siddiqui, Muayad F Almahariq, Inga S Grills, Craig W Stevens Abstract Introduction: Malignant pleural mesothelioma (MPM) is a devastating disease with poor survival outcomes for most patients. Optimizing therapeutic approaches is thus vital, but has been hampered by a dearth of…
Read MoreImpairments in Bowel Function, Social Function and Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Annals of Surgical Oncology 2020 January [Link] Zubair Bayat, Emily L Taylor, Danielle A Bischof, J Andrea McCart, Anand Govindarajan Abstract Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can be associated with decreases in quality of life (QOL). Bowel-related QOL (BR-QOL) after CRS-HIPEC has not been previously studied. The objectives of the current study…
Read MoreLocalized Biphasic Malignant Mesothelioma Presenting as a Giant Pelvic Wall Mass: A Rare Case Report and Literature Review
BMC Medical Imaging 2020 May 6 [Link] Yunsong Liu, Jingjun Wu, Ying Zhao, Pengxin Zhang, Zhengyu Hua, Wan Dong, Tao Lin, Ailian Liu Abstract Background: Localized biphasic MPeM is rare in clinical practice, we reviewed 8 cases of localized biphasic MPeM (including our present case), and summarized the clinical and imaging features of the disease.…
Read MoreTreatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
Thoracic Cancer 2020 May 4 [Link] Trama A, Proto C, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Falcini F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G,…
Read MoreSurgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
Frontiers in Oncology 2020 March 24 [Link] Breen WG, Garces YI, Olivier KR, Park SS, Merrell KW, Nichols FC, Peikert TD, Molina JR, Mansfield AS, Roden AC, Blackmon SH, Wigle DA Abstract Background: The optimal treatment sequence for localized malignant pleural mesothelioma (MPM) is controversial. We aimed to assess outcomes and toxicities of treating localized…
Read MoreSurgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
Translational Lung Cancer Research 2020 February [Link] Woodard GA, Jablons DM Abstract Extrapleural pneumonectomy (EPP) and pleurectomy decortication (PD) are radical operations for malignant pleural mesothelioma (MPM) that remain controversial among thoracic surgeons. There is a lack of randomized evidence to support a survival benefit when major surgical resection is included in multi-modality treatment regimens.…
Read MoreRoutine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
The Journal of Thoracic and Cardiovascular Surgery 2020 January 30 [Link] De León LE, Bravo-Iñiguez CE, Fox S, Tarascio J, Freyaldenhoven S, Lapidot M, Jaklitsch MT, Bueno R Abstract OBJECTIVE: The purpose of this study was to determine the incidence of venous thromboembolism and utility of a routine surveillance program in patients undergoing surgery for…
Read More